Polymeric micelle mediated follicular delivery of spironolactone: Targeting the mineralocorticoid receptor to prevent glucocorticoid-induced activation and delayed cutaneous wound healing.

Détails

Ressource 1Télécharger: 1-s2.0-S0378517321005780-main.pdf (6729.56 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_AD1EA3AD275D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Polymeric micelle mediated follicular delivery of spironolactone: Targeting the mineralocorticoid receptor to prevent glucocorticoid-induced activation and delayed cutaneous wound healing.
Périodique
International journal of pharmaceutics
Auteur⸱e⸱s
Dahmana N., Mugnier T., Gabriel D., Favez T., Kowalczuk L., Behar-Cohen F., Gurny R., Kalia Y.N.
ISSN
1873-3476 (Electronic)
ISSN-L
0378-5173
Statut éditorial
Publié
Date de publication
04/06/2021
Peer-reviewed
Oui
Volume
604
Pages
120773
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Résumé
Impaired wound healing in patients receiving glucocorticoid therapy is a serious clinical concern: mineralocorticoid receptor (MR) antagonists can counter glucocorticoid-induced off-target activation of MR receptors. The aim of this study was to investigate the cutaneous delivery of the potent MR antagonist, spironolactone (SPL), from polymeric micelle nanocarriers, prepared using a biodegradable copolymer, methoxy-poly(ethylene glycol)-di-hexyl-substituted-poly(lactic acid). Immunofluorescent labelling of the MR showed that it was principally located in the pilosebaceous unit (PSU), justifying the study rationale since polymeric micelles accumulate preferentially in appendageal structures. Cutaneous biodistribution studies under infinite and finite dose conditions, demonstrated delivery of pharmacologically relevant amounts of SPL to the epidermis and upper dermis. Preferential PSU targeting was confirmed by comparing amounts of SPL in PSU-containing and PSU-free skin biopsies: SPL nanomicelles showed 5-fold higher delivery of SPL in the PSU-containing biopsies, 0.54 ± 0.18 ng/mm <sup>2</sup> vs. 0.10 ± 0.03 ng/mm <sup>2</sup> , after application of a hydrogel in finite conditions. Canrenone, an active metabolite of SPL, was also quantified in skin samples. In addition to being used for the treatment of delayed cutaneous wound healing by site-specific antagonism of the MR, the formulation might also be used to treat pilosebaceous androgen-related skin diseases, e.g. acne vulgaris, since SPL is a potent androgen receptor antagonist.
Mots-clé
Acne, Androgen receptor antagonist, Cutaneous biodistribution, Follicular delivery, Immunofluorescence, Methoxy-poly(ethylene glycol)-di-hexyl-substituted-poly(lactic acid), Micelles, Mineralocorticoid receptor, Spironolactone, Wound healing
Pubmed
Open Access
Oui
Création de la notice
15/06/2021 16:03
Dernière modification de la notice
19/06/2021 7:12
Données d'usage